Palliative Short Course Radiotherapy for Advanced Thoracic Cancer
Palliative Short Course Accelerated Radiation Therapy for Advanced Thoracic Cancer
1 other identifier
interventional
53
1 country
1
Brief Summary
The study wants to define the maximum tolerated dose (MTD), safety and efficacy of a short course radiation therapy in patients with symptomatic advanced thoracic cancer.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Jan 2009
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2009
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2018
CompletedFirst Submitted
Initial submission to the registry
March 8, 2018
CompletedFirst Posted
Study publicly available on registry
March 14, 2018
CompletedMarch 14, 2018
March 1, 2018
9 years
March 8, 2018
March 8, 2018
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Maximum tolerated dose
The maximum tolerated dose is defined as the dose level below the highest administered dose associated with dose limiting toxicity (DLT) in at least one third of patients
1 year
Secondary Outcomes (4)
Acute toxicity
1 year
Quality of life
1 year
Pain relief
1 year
Late toxicity
1 year
Study Arms (1)
Short course radiotherapy
EXPERIMENTALThe radiotherapy is delivered over 2 days with accelerated hypo-fractionation.
Interventions
An accelerated hypo-fractionation radiotherapy is delivered for palliation in patients with advanced thoracic cancer
Eligibility Criteria
You may qualify if:
- histologically proven advanced thoracic cancer
- excluded from curative therapy because of disease stage and/or presence of multiple comorbidities and/or poor performance status
- age \> 18 years
- Eastern Cooperative Oncology Group (ECOG) \<3
You may not qualify if:
- \- prior radiotherapy to the same region
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Radiation Oncology Center, Dept. of Experimental, Diagnostic and Specialty Medicine - DIMES, University of Bologna, S.Orsola-Malpighi Hospital
Bologna, 40100, Italy
Related Publications (1)
Farina E, Macchia G, Buwenge M, Siepe G, Zamagni A, Cammelli S, Cilla S, Wondemagegnhu T, Woldemariam AA, Uddin AFMK, Sumon MA, Cellini F, Deodato F, Morganti AG. Radiotherapy in palliation of thoracic tumors: a phase I-II study (SHARON project). Clin Exp Metastasis. 2018 Dec;35(8):739-746. doi: 10.1007/s10585-018-9942-6. Epub 2018 Oct 8.
PMID: 30298381DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Alessio G. Morganti, MD
Radiation Oncology Center, Dept. of Experimental, Diagnostic and Specialty Medicine - DIMES, University of Bologna, S.Orsola-Malpighi Hospital, Bologna, Italy
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
March 8, 2018
First Posted
March 14, 2018
Study Start
January 1, 2009
Primary Completion
January 1, 2018
Study Completion
January 1, 2018
Last Updated
March 14, 2018
Record last verified: 2018-03